Zealand Pharma's Phase 2 trial was an 'uniquivocal win' for a drug that can treat both liver disease and obesity, analysts said.
Shares of Denmark's Zealand Pharma rose 35% on Monday after results showed success in its liver disease treatment survodutide, which is also on trial as a drug to treat obesity.
The Phase 2 trial of the survodutide drug showed 83% of adults saw positive results for a form of liver inflammation caused by excess fat cells known as "MASH," the company said in an announcement Monday. Analysts latched onto the drug's possible efficacity in obesity research after the latest test results, which indicated the safety of the top dosage used in that trial.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gene therapy at CHOP allowed a deaf boy to hear. But some deaf people object to the treatment.A second deaf patient is undergoing the treatment, produced by Eli Lilly, at CHOP on Friday.
Read more »
Novo Nordisk settles two lawsuits over copycat versions of Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlookTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Read more »
Lilly Ledbetter Fair Pay Act’s 15th Anniversary—The History And ImpactHolly C. Corbett is a trained journalist and brand builder with multimedia expertise that spans from the written word to podcasts to video to curriculum creation. She has held leadership positions at established global media brands, social impact organizations, and content startups.
Read more »
Eli Gold will no longer call Crimson Tide football gamesEli Gold, also known as the voice of the Alabama Crimson Tide will no longer serve in the role of announcer, according to the University of Alabama.
Read more »
Can Denmark's world-beating drugs maker stay ahead?Thanks to its weight loss drug, Novo Nordisk briefly became Europe's most valuable firm in 2023.
Read more »